Rapid sequence intubation and the role of the emergency medicine pharmacist: 2022 update.

Purpose: The dosing, potential adverse effects, and clinical outcomes of the most commonly utilized pharmacologic agents for rapid sequence intubation (RSI) are reviewed for the practicing emergency medicine pharmacist (EMP).

Summary: RSI is the process of establishing a safe, functional respiratory system in patients unable to effectively breathe on their own. Various medications are chosen to sedate and even paralyze the patient to facilitate an efficient endotracheal intubation.

"Not for human consumption": a review of emerging designer drugs.

Synthetic, or "designer" drugs, are created by manipulating the chemical structures of other psychoactive drugs so that the resulting product is structurally similar but not identical to illegal psychoactive drugs. Originally developed in the 1960s as a way to evade existing drug laws, the use of designer drugs has increased dramatically over the past few years. These drugs are deceptively packaged as "research chemicals," "incense," "bath salts," or "plant food," among other names, with labels that may contain warnings such as "not for human consumption" or "not for sale to minors.

Rapid-sequence intubation and the role of the emergency department pharmacist.

Purpose: The pharmacology, pharmacokinetics, safety, and dosing of medications used during the pretreatment and paralysis with induction steps of rapid-sequence intubation (RSI) and the role of the pharmacist in RSI are reviewed.

Summary: RSI is a process involving the administration of a sedative induction agent and a paralytic agent to facilitate endotracheal intubation. This is a procedure in which the emergency department (ED) pharmacist can play an integral role, especially in the steps of pretreatment, paralysis with induction, and postintubation management.